New treatment could be ‘breakthrough’ for vitiligo
Recent implementation of ultraviolet-B light therapy in addition to the oral medication Xeljanz (tofacitinib) has resulted in “dramatic” outcomes in the study patients. While the initial findings of this theory provided what appear to be positive results, more studies need to be conducted to provide supplementary support of this combination of therapies. In addition, larger study groups should be researched to determine appropriate dosing, length of therapy, and the like. Regardless of the present lack of supporting evidence, there is great promise in providing UVB light therapy in partner with tofacitinib to clear vitiligo.